Literature DB >> 20967737

Phase I and II metabolites of speciogynine, a diastereomer of the main Kratom alkaloid mitragynine, identified in rat and human urine by liquid chromatography coupled to low- and high-resolution linear ion trap mass spectrometry.

Anika A Philipp1, Dirk K Wissenbach, Armin A Weber, Josef Zapp, Hans H Maurer.   

Abstract

Mitragyna speciosa (Kratom in Thai), a Thai medical plant, is misused as herbal drug of abuse. Besides the most abundant alkaloids mitragynine (MG) and paynantheine (PAY), several other alkaloids were isolated from Kratom leaves, among them the third abundant alkaloid is speciogynine (SG), a diastereomer of MG. The aim of this present study was to identify the phase I and II metabolites of SG in rat urine after the administration of a rather high dose of the pure alkaloid and then to confirm these findings using human urine samples after Kratom use. The applied liquid chromatography coupled to low- and high-resolution mass spectrometry (LC-HRMS-MS) provided detailed information on the structure in the MS(n) mode particularly with high resolution. For the analysis of the human samples, the LC separation had to be improved markedly allowing the separation of SG and its metabolites from its diastereomer MG and its metabolites. In analogy to MG, besides SG, nine phase I and eight phase II metabolites could be identified in rat urine, but only three phase I and five phase II metabolites in human urine. These differences may be caused by the lower SG dose applied by the user of Kratom preparations. SG and its metabolites could be differentiated in the human samples from the diastereomeric MG and its metabolites comparing the different retention times determined after application of the single alkaloids to rats. In addition, some differences in MS(2) and/or MS(3) spectra of the corresponding diastereomers were observed.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20967737     DOI: 10.1002/jms.1848

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  7 in total

Review 1.  Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines.

Authors:  Christopher D Rosenbaum; Stephanie P Carreiro; Kavita M Babu
Journal:  J Med Toxicol       Date:  2012-03

Review 2.  The pharmacology and toxicology of kratom: from traditional herb to drug of abuse.

Authors:  Marcus L Warner; Nellie C Kaufman; Oliver Grundmann
Journal:  Int J Legal Med       Date:  2015-10-28       Impact factor: 2.686

3.  Evaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Jun Lu; Heming Wei; Jianjun Wu; Mohd Fadzly Amar Jamil; Mei Lan Tan; Mohd Ilham Adenan; Philip Wong; Winston Shim
Journal:  PLoS One       Date:  2014-12-23       Impact factor: 3.240

Review 4.  Novel Psychoactive Substances-Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs.

Authors:  Zurina Hassan; Oliver G Bosch; Darshan Singh; Suresh Narayanan; B Vicknasingam Kasinather; Erich Seifritz; Johannes Kornhuber; Boris B Quednow; Christian P Müller
Journal:  Front Psychiatry       Date:  2017-08-18       Impact factor: 4.157

Review 5.  The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research.

Authors:  Jack E Henningfield; Reginald V Fant; Daniel W Wang
Journal:  Psychopharmacology (Berl)       Date:  2017-12-23       Impact factor: 4.530

Review 6.  The Chemical and Pharmacological Properties of Mitragynine and Its Diastereomers: An Insight Review.

Authors:  Thiruventhan Karunakaran; Kok Zhuo Ngew; Ahmad Alif Danial Zailan; Vivien Yi Mian Jong; Mohamad Hafizi Abu Bakar
Journal:  Front Pharmacol       Date:  2022-02-24       Impact factor: 5.810

Review 7.  Mitragyna Species as Pharmacological Agents: From Abuse to Promising Pharmaceutical Products.

Authors:  Islamudin Ahmad; Wisnu Cahyo Prabowo; Muhammad Arifuddin; Jaka Fadraersada; Niken Indriyanti; Herman Herman; Reza Yuridian Purwoko; Firzan Nainu; Anton Rahmadi; Swandari Paramita; Hadi Kuncoro; Nur Mita; Angga Cipta Narsa; Fajar Prasetya; Arsyik Ibrahim; Laode Rijai; Gemini Alam; Abdul Mun'im; Sukanya Dej-Adisai
Journal:  Life (Basel)       Date:  2022-01-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.